CCP 07

Drug Profile

CCP 07

Alternative Names: CCP-07

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Vernalis
  • Developer Tris Pharma
  • Class Antitussives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Common cold; Cough

Most Recent Events

  • 21 Feb 2017 Versalis expects approval of NDA by US FDA for CCP 07 for Common cold and Cough
  • 21 Sep 2016 Planned Prescription Drug User Fee Act (PDUFA) date for Common cold in USA (PO) is 2017-04-20
  • 21 Sep 2016 Planned Prescription Drug User Fee Act (PDUFA) date for Cough in USA (PO) is 2017-04-20
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top